The locus coeruleus-noradrenergic systems supplies norepinephrine throughout the central nervous system. State-dependent neuronal discharge activity of locus coeruleus noradrenergic neurons has long-suggested a role of this system in the induction of an alert waking state. Work over the past two decades provides unambiguous evidence that the locus coeruleus, and likely other noradrenergic nuclei, exert potent wake-promoting actions via an activation of noradrenergic β-and α 1 -receptors located within multiple subcortical structures, including the general regions of the medial septal area, the medial preoptic area and, most recently, the lateral hypothalamus. Conversely, global blockade of β-and α 1 -receptors or suppression of norepinephrine release results in profound sedation. The wake-promoting action of central noradrenergic neurotransmission has clinical implications for treatment of sleep/arousal disorders, such as insomnia and narcolepsy, and clinical conditions associated with excessive arousal, such as posttraumatic stress disorder.
Introduction
The regulation of sleep and waking serves a critical role in behavior and ultimately survival. Moreover, during waking, arousal levels fluctuate, ranging from sleepiness/sedation associated with a relative insensitivity to sensory stimuli to high-arousal stress or fearrelated conditions associated with a hypersensitivity to sensory events (hyperalertness, hypervigilance). Fluctuations in sleep-wake/arousal state are accompanied by alterations in forebrain neuronal activity that are reflected in electroencephalographic (EEG) signals. 1, 2 The formal examination of the neurobiology of arousal/waking dates back to the work of von Economo 3 , Bremer 4 and Moruzzi and Magoun 5 , which identified a critical role of the brainstem in the induction and maintenance of arousal. Subsequent work has identified a large array of brainstem and basal forebrain neural systems that participate in the regulation of behavioral state. Included among these is the locus coeruleus (LC)-noradrenergic system.
The LC is a small pontine nucleus that provides the majority of brain norepinephrine (NE). 6 NE acts at three major receptor families, α 1 , α 2 , and β, each comprised of multiple subtypes. α 1 -and β-receptors are thought to exist primarily postsynaptically whereas α 2 -receptors are present both pre-and postsynaptically. Early electrophysiological observations indicated that the LC-NE system may play a role in the regulation of behavioral state. 6, 7 For example, LC neurons display higher discharge rates during waking than in sleep while within waking LC discharge rate is positively correlated with behavioral and EEG indices of arousal. [8] [9] [10] Importantly, these alterations in LC discharge rate precede changes in behavioral state. [8] [9] [10] Combined, these observations suggested a potentially causal role of the LC-noradrenergic system in the regulation of sleep-wake/arousal state. Results from studies conducted over the past two decades provide unambiguous evidence for a prominent wake/arousal-promoting role of the LC and other brain noradrenergic systems (e.g. A1, A2), as reviewed below.
Wake/Arousal-Promoting Actions of the Locus Coeruleus
Early lesion and pharmacological studies attempted to address whether there exists a causal relationship between LC neuronal activity and behavioral and EEG indices of waking/ arousal (for review 11, 12 ). In general, lesions of noradrenergic systems have had an inconsistent impact on indices of arousal (for review 12 ). There is now strong reason to believe this limited action of noradrenergic lesions on behavioral state likely reflects the occurrence of time-dependent lesion-induced compensation within noradrenergic systems (for review 12 ). Compensation is apparent within 7-10 days following a lesion and is observed at the level of release, receptor number, and second messenger sensitivity. 12 For example, microdialysis measures of transmitter release unambiguously demonstrate that within 7-10 days following noradrenergic or dopaminergic lesions, extracellular levels of NE and dopamine are not significantly reduced unless tissue levels have been decreased by more than 90%. [13] [14] [15] [16] The vast majority of studies using catecholamine lesions generally do not achieve tissue depletion greater than 80-85%. Moreover, even when tissue levels have been reduced by at least 90%, the decrease in extracellular levels of these transmitters is substantially less than that observed in tissue measures (e.g. 60% reduction in extracellular levels vs. >90% reduction in tissue levels). Given lesions also increase postsynaptic receptor number and second messenger levels, the functional impairment in NE neurotransmission associated with these larger lesions (> 90% tissue depletion) is likely to be substantially less than predicted by the decrease in extracellular NE levels. Given these observations, it is not surprising that the time course of the sleep-wake effects of NE lesions is identical to that seen with lesion-induced compensation within catecholamine systems. For example, Lidbrink 17, 18 reported that 6-OHDA lesions of the dorsal noradrenergic bundle initially increased slow-wave EEG activity, but by approximately 7 days following the lesion this effect was no longer apparent.
In contrast to lesions, acute suppression of LC-NE neurotransmission by systemic, ICV, or intra-brainstem administration of α 2 -receptor agonists, which in part activate presynaptic autoreceptors and thereby inhibit NE neurotransmission at postsynatpic noradrenergic receptors, elicit profound sedation. 19, 20 Despite the consistency of these observations, the small size of the LC and the close proximity of this nucleus to other brainstem arousalrelated nuclei preclude drawing unambiguous conclusions regarding the role of the LC vs. other brainstem nuclei in these drug-induced changes in arousal state.
To more selectively manipulate LC neuronal discharge activity, Adams and Foote developed a combined recording/infusion probe that uses electrophysiological recordings to guide placement of an infusion needle within a 200-300 microns distance from the LC and to monitor the electrophysiological effects at LC neurons of peri-LC infusions of drugs that either activate or inhibit LC neuronal discharge rate. 21, 22 With the consistent placement of the infusion needle in close proximity to the LC, much smaller infusion volumes (35-150 nl) can be used, greatly limiting the spread of infusate beyond the boundaries of the LC. Using this probe, we demonstrated that unilateral LC activation (via infusion of the cholinergic agonist, bethanechol) produced a bilateral activation of forebrain EEG in the halothaneanesthetized rat (Figure 1) . 22 A number of observations indicated that infusion-induced alterations in LC discharge were responsible for EEG activation, rather than drug action at a site distant to the LC. These include: 1) LC activation always preceded EEG activation by only a few seconds; 2) infusions only activated forebrain EEG if they were placed within a radius of approximately 500 μm of the center of the LC, a radius that rules out participation of a number of brainstem nuclei ( Figure 1); 3) a similar latency between LC activation and EEG activation was observed regardless of whether infusions were placed lateral or medial to the LC; 4) infusions placed anterior or posterior to the LC did not alter forebrain EEG activity state; and 5) EEG activation was prevented by pretreatment with drugs that suppress NE neurotransmission (an α 2 -agonist and a β-antagonist).
Additional studies in the lightly-anesthetized rat displaying spontaneously activated (desynchronized) forebrain EEG, demonstrated that bilateral suppression of LC neuronal discharge (via 35 nl infusions of an α 2 -receptor agonist) produced a robust increase in slowwave EEG activity ( Figure 2) . 23 In these studies, anesthesia level was adjusted to elicit sustained, spontaneous desynchronized forebrain EEG, indicative of a lightly anesthetized state. Under these conditions, EEG activity and LC neuronal discharge rates were monitored before and following suppression of LC neuronal firing produced by 35 nl infusions of the α 2 -agonist, clonidine. Bilateral, but not unilateral, clonidine infusions robustly suppressed desynchronized EEG activity and increased slow-wave activity. Importantly, these studies document that even minimal LC neuronal discharge activity within a single hemisphere (i.e. 5-10% of basal levels) is sufficient to maintain bilateral forebrain activation. This is likely an important factor for why LC/noradrenergic lesions, which almost certainly never destroy all LC NE neurons and thereby fail to reduce completely extracellular NE levels do not result in large alterations in time spent awake (see above).
These observations indicate that LC neuronal activity is both sufficient and necessary for the maintenance of an activated forebrain in the anesthetized rat. More recent studies using optogenetic activation of the LC observed similar arousal-promoting actions in unanesthetized animals. 24 These studies demonstrate that brief activation of the LC in the range of 3-5 Hz elicits increases in EEG/EMG measures of waking. This effect was most consistent when the duration of activation was at least 5-8 seconds, consistent with observations in anesthetized animals described above. Conversely, inhibition of the LC for 1-hour decreased time spent awake in the active period of the animal's circadian cycle, while not altering time spent asleep. This is particularly notable given that 10-minute optogenetic inhibition of the LC only decreased extracellular levels in the prefrontal cortex by approximately 50% 24 , suggesting that perhaps not all LC discharge activity was suppressed. The above-reviewed observations in anesthetized animals demonstrated that only near-complete suppression of LC discharge (bilaterally) resulted in an increase in EEG indices of sedation. Thus, it seems likely that a more profound suppression of LC-NE neurotransmission would elicit greater actions on sleep-wake state than observed in these optogenetic studies.
Neurocircuitry and Receptor Mechanisms of Noradrenergic Dependent
Waking: Wake-Promoting Actions of α 1 -and β-Receptors in the Medial
Septal and Medial Preoptic Areas
Collectively the observations reviewed above provide strong evidence that the LC-NE system exerts wake-promoting actions. This raises the question of which LC terminal fields and which receptor post-synaptic receptors participate in these actions. Subcortically, the general regions of the medial septal area (MSA), the medial preoptic area (MPOA), and the substantia innominata (SI) are known to modulate forebrain EEG activity state [25] [26] [27] and each of these regions receives LC-noradrenergic input. [28] [29] [30] A series of studies examined whether NE acts within these subcortical regions to promote waking. In these studies, the sleep-wake/arousal effects of intratissue infusion of NE, a noradrenergic α 1 -receptor agonist (phenylephrine) or a noradrenergic β-receptor agonist (isoproterenol) was examined in anesthetized and unanesthetized rats. [31] [32] [33] [34] In unanesthetized animals, the effects of wakepromoting actions of remote-controlled infusions of NE and NE agonists were examined in sleeping animals implanted with EEG/EMG electrodes. This approach permitted examination of the wake/arousal-promoting actions of the infusions from a stable and lowarousal state (i.e. sleeping) while avoiding infusion-related handling of the animals (see 32 ).
Wake-promoting actions of NE β-and α 1 -receptors within the MSA and MPOA, but not SI These studies demonstrated that intratissue infusion (150 nl-250 nl) of β-or α 1 -receptor agonists (isoproterenol or phenylephrine, respectively) into the MSA or MPOA (situated immediately caudal to the MSA; Figures 3-5) produce robust and dose-dependent increases in EEG activation in anesthetized animals and EEG/behavioral indices of waking in unanesthetized animals. [31] [32] [33] [34] [35] [36] Infusions immediately outside these regions were devoid of wake-promoting actions. [31] [32] [33] [34] In unanesthetized animals, the wake-promoting actions of β-and α 1 -receptors within both the MSA and MPOA were additive but not supra-additive/ synergistic (i.e. greater than the sum of the individual effects of β-and α 1 -receptors; Figure  5 34 ).
There are three identified β-receptor subtypes: β 1 -β 3 . 12 Intra-tissue infusions of the β 2 -agonist, clenbuterol, into either the MSA or the MPOA produced dose-dependent increases in time spent awake similar to that seen with the non-selective β-agonist, isoproterenol 37 . In addition to its β 2 -agonist action, clenbuterol also possesses weak β 1 -antagonistic properties 38 . However, infusion of a selective β 1 -antagonist into the MSA or MPOA had no impact on sleep-wake state 37 , indicating that clenbuterol-induced waking results from activation of β 2 -receptors and not inhibition of β 1 -receptors.
The SI, situated immediately lateral to both the MSA and MPOA (see Figure 3 ), provides a potent activating influence on forebrain EEG. 27, 39 These SI projections act in parallel with efferents from the MSA to regulate the activity state of the neocortex and hippocampus, respectively. Thus, it was posited initially that NE-driven activation of hippocampal and cortical EEG involved the simultaneous actions of NE within the MSA and SI, respectively. However, infusion of NE, phenylephrine (α 1 -agonist), isoproterenol (βagonist), or the indirect noradrenergic agonist, amphetamine, directly into the SI failed to impact EEG/EMG or behavioral indices of waking/arousal ( Figure 4 ). [31] [32] [33] 40 In contrast, under identical experimental conditions, intra-SI infusions of the excitatory amino acid, glutamate, produced a robust activation of forebrain EEG. 27, 31 Across all drug-infusion studies, the only condition in which a noradrenergic drug was observed to promote waking when infused into SI was with the highest concentration of NE examined (15 μg/250 nl) which produced a moderate increase in waking ( Figure 4 ). 33, 41 However, in this case, the latency to waking was substantially longer and the time spent awake substantially reduced relative to infusion into the MPOA (Figure 4 ) 33 , suggesting that at high concentrations NE diffuses from the SI to the MPOA where it acts to increase waking.
Collectively, these observations demonstrate NE acts at β-and α 1 -receptors within the MSA and MPOA, but not SI, to promote waking. Limited studies reported minimal sleep-wake actions of the α 1 -agonist, methoxamine, when infused into the MPOA. 42, 43 Although the basis for this apparent discrepancy is unclear, possible contributing factors include an elevated baseline level of waking, which would obscure the acute wake-promoting actions of an infusion, and more extensive needle/cannula-related tissue damage within the MPOA in these latter studies.
Neurocircuitry within the MSA and MPOA involved in NE-induced waking
The terms MSA and MPOA refer to relatively large and heterogeneous structures, each containing multiple subnuclei. The anatomical resolution of previous mapping studies (approximately 500 μm) limits definitive identification of the specific subnuclei involved in the wake-promoting actions of NE within these general regions. Distinct populations of sleep-active and wake-active neurons are found in the general regions of the MSA and MPOA. Within the MPOA, sleep-active neurons are found within both the median preoptic nucleus (MnPN) and the ventrolateral preoptic nucleus (VLPO). 44, 45 Results from previous NE/NE-agonist mapping studies suggest that proximity to the VLPO does not correlate with the wake-promoting effects of intra-MPOA α 1 -agonist infusion. 33 On the other hand, the MnPN is well within the general area targeted in previous intra-MPOA infusion studies.
Neither α 1 -or β-agonists affect sleep-active neurons within MPOA and MSA. 46 In contrast, α 1 -agonist administration, but not β-agonist, increases the activity of a subpopulation of waking-active neurons 46 . Thus, α 1 -receptor-dependent waking may involve an activation of waking-active neurons in the MSA and MPOA. Within the SI and MPOA, sleep-active neurons express α 2 -receptors and α 2 -receptor stimulation was observed to inhibit sleepactive neurons within the MSA and MPOA. 46, 47, 48 Thus, the wake-promoting actions of NE may also involve α 2 -receptor-dependent inhibition of sleep-active neurons.
Within the MSA, evidence indicates that the activity of GABAergic and cholinergic neurons combine to influence hippocampal EEG activity. 49 To date, the extent to which α 1 -and β-receptors are differentially distributed across neurochemically-defined (i.e. cholinergic vs. GABAergic vs. galaninergic) or behaviorally-defined (i.e. sleep-active vs. waking-active) neuronal subpopulations within both the MSA and MPOA is unknown. If the wakepromoting effects of α 1 -and β-receptors involve actions on the same cell, at least two mechanisms exist through which these receptors could interact to exert additive arousalmodulating actions. First, these receptors could exert independent and additive effects on membrane potential via parallel actions on second messenger systems (e.g. phosphoinositol and cAMP). Additionally, evidence indicates that α 1 -receptors can potentiate β-receptormediated cAMP production. 50 However, this latter mechanism would not explain why βantagonists fail to exert sedative effects alone but potentiate the sedative effects of α 1 -antagonists, as described below (see Synergistic Actions of β-and α 1 -Receptors in the Maintenance of Alert Waking).
In addition to hippocampal projections, the MSA also sends direct projections to the neocortex. [51] [52] [53] Therefore, NE could simultaneously modulate hippocampal and cortical EEG activity state via simultaneous actions on both of these ascending MSA projections paths. Alternatively, NE could influence EEG and behavioral activity state via alterations in efferent pathways that project to subcortical arousal-related regions, such as the hypothalamus, thalamus, or midbrain. Such actions could involve direct projections from the MSA to these regions 54, 55 or indirect via hippocampal efferents. 56, 57 Contrasting actions of MSA/MPOA β-receptor blockade in anesthetized vs. unanesthetized animals As reviewed above, stimulation of β-receptors within the MSA is sufficient to increase EEG and behavioral indices of waking/arousal. Moreover, in the lightly-anesthetized animal, bilateral blockade of MSA β-receptors decreases EEG activation elicited either through LC activation or in the lightly-anesthetized preparation. 58 These observations indicate that in the anesthetized animal MSA β-receptors are necessary for forebrain EEG activation. Whether this is true of MPOA β-receptors remains to be determined. In contrast, in the unanesthetized rat, neither bilateral blockade of MSA β-receptors 58 or blockade of MPOA β-receptors 35 alters EEG or behavioral indices of arousal. Nonetheless, global suppression of LC-NE neurotransmission, using ICV or intrabrainstem-administered α 2 -agonists, potently decreases EEG/behavioral indices of arousal. 59, 60 The lack of sedative effects of bilateral MSA/MPOA β-receptor blockade likely reflects the wake-promoting actions of: 1) α 1 -receptors within these regions; and/or 2) α 1 -and β-receptors located outside these regions. In sum, in contrast to that observed in the presence of anesthesia, the wakepromoting actions of MSA β-receptors are not necessary for behavioral and EEG indices of alert waking even though stimulation of these β-receptors is sufficient to promote alert waking.
Origin and organization of the noradrenergic innervation of the MSA, MPOA and SI
The above-described observations indicate that LC neurons exert a robust excitatory influence on forebrain activity state, actions that likely involve NE signaling within the MSA and MPOA. However, there are a number of additional noradrenergic nuclei that could also provide input to these regions and thus participate in the modulation of behavioral state. Recent retrograde tracing studies indicate that although the LC provides the majority of noradrenergic input to the MSA, MPOA and SI (~50%), the A1/C1 (~25%) and A2/C2 (~25-40%) cell groups also provide notable contributions. 30 These observations suggest a likely arousal-promoting role of the A1/C1 and the A2/C2 noradrenergic/adrenergic nuclei.
In the case of the LC, basal forebrain-projecting noradrenergic neurons are largely distributed uniformly within the LC. 30 This contrasts with a rough topographic distribution of LC neurons projecting to neocortex (with the exception of the prefrontal cortex), hippocampus, cerebellum, and spinal cord. 61 Additional observations indicate that individual LC neurons display a high degree of collateralization across these three arousalrelated basal forebrain regions, ensuring that alterations in LC discharge are relayed simultaneously to these regions. 30 In sum, these observations indicate that LC efferents exert coordinated actions across multiple anatomically-distinct, yet functionally-related (i.e. arousal-related), basal forebrain fields.
As mentioned, unlike the MSA and MPOA, the SI is relatively insensitive to the wakepromoting actions of NE and NE agonists. 33, 40 Nonetheless, in vitro, NE depolarizes cholinergic basal forebrain neurons, indicating a neuromodulatory role of NE within this region. 62 To date, the behavioral/cognitive functions of NE within the SI remain to be fully elucidated. However, evidence indicates a role of the SI in state-dependent attentional processes (for review 63 ). Moreover, noradrenergic α 1 -receptors within the SI appear to participate in the priming effect of systemic epinephrine administration on the cerebral auditory evoked potential. 64 Thus, NE likely acts within the SI to modulate state-dependent behavioral/cognitive processes, such as attention. The high degree of collateralization across the MSA, MPOA and SI permits the LC to simultaneously modulate behavioral state while modulating SI-dependent behavioral and physiological processes.
Additional Regions Involved in NE-Dependent Waking
In addition to the MSA and MPOA, the lateral hypothalamus (LH) has been implicated in the regulation of sleep-wake state and state-dependent processes. 65, 66 In particular, the neuropeptide family, hypocretin (HCRT; orexin), exerts potent wake-promoting actions. 67, 68 HCRT-synthesizing neurons are located solely in the perifornical region of the LH, an area that receives a moderately dense noradrenergic innervation most of which arises from outside the LC. 69, 70 Recently completed studies demonstrate additive wake-promoting actions of α 1 -and β-receptor agonists (phenylephrine and isoproterenol, respectively) infused into the LH (Figure 6 ). 71 Surprisingly, this NE-dependent waking was not associated with an activation of HCRT neurons as measured by expression of the immediate-early gene, c-fos. 71 This latter observation is consistent with in vitro electrophysiological studies demonstrating an inhibitory action of NE on HCRT neuronal discharge under certain conditions 72, 73 (but see 74 ). Thus, the wake-promoting actions of NE within the LH may be independent of the HCRT system. However, this is clearly a question that needs further study.
Finally, there are numerous additional sites in which NE may act to modulate behavioral state and state-dependent processes. For example, within neocortex and thalamus, NE exerts a depolarizing action, eliciting a transition from a burst-mode of firing associated with sleep to a single-spike mode of firing associated with waking. 75, 76 Moreover, a variety of additional brainstem-originating monoaminergic systems are known to modulate sleepwake/arousal state including, serotonergic, dopaminergic, cholinergic and histaminergic systems. 11, 25, 77, 78 All of these systems are highly interconnected and in many cases have been demonstrated to exert reciprocally activating effects. [79] [80] [81] To date, the full extent to which NE acts on these other neurotransmitter systems to modulate behavioral state has not been examined systematically. Nonetheless, dorsal pontine tegmental β-receptor activation has been demonstrated to inhibit REM sleep. 82 Combined, these observations indicate that noradrenergic regulation of behavioral state involves coordinated actions of NE, arising from the LC and other noradrenergic nuclei (i.e. A1, A2), across a distributed network of cortical and subcortical structures.
Synergistic Actions of β-and α 1 -Receptors in the Maintenance of Alert Waking
Substantial evidence indicates that stimulation of either α 1 -or β-receptors within any one of a number of brain regions is sufficient to induce the alert waking state. This high degree of redundancy suggests that α 1 -/β-receptor action in any given region is unlikely to be necessary for the maintenance of alert waking, consistent with observations reviewed above regarding a lack of effect of β-antagonist infusions into the MSA on indices of arousal in unanesthetized animals. To initially address the degree to which α 1 -and/or β-receptors, globally within the brain, are necessary for the maintenance of alert waking, the EEG effects of β-receptor blockade (ICV timolol), α 1 -receptor blockade (intraperitoneal prazosin), or combined β-and α 1 -receptor blockade were examined in rats under conditions associated with high arousal levels (a brightly-lit novel environment). Combined blockade of β-and α 1 -receptors elicited a profound increase in large-amplitude, slow-wave activity in cortical EEG indicative of sedation ( Figure 7) . 83 This increase in slow-wave activity was in contrast to the minimal EEG effects of β-antagonist treatment alone or an increase in sleep-spindles seen with α 1 -receptor blockade (Figure 7 ; see also 84 ). Therefore, under these conditions, combined blockade of β-and α 1 -receptors produces synergistic sedative effects.
Interestingly, the sedative action of combined β-/α 1 -receptor blockade was not observed during the first 5-minutes of testing. Thus, under certain conditions of elevated arousal, combined actions of α 1 -and β-receptors are not necessary for the maintenance of EEG indices of arousal. These observations could suggest that the combined blockade of α 1 -and β-receptors increases the rate of habituation to an arousing, novel environment. Alternatively, initial exposure to the novel environment may involve actions of additional arousal-promoting systems that are capable of compensating for the loss of noradrenergic signaling.
Finally, it is of interest that although combined α 1 -and β-receptor blockade elicits profound sedation (i.e. nearly continuous slow-wave EEG activity), this treatment did not appear to induce sleep. Specifically, the animals maintained sufficient postural tone to remain in an upright position, albeit with minimal movement. Thus, in the absence of α 1 -/β-receptor action, actions of post-synaptic α 2 -receptors or other neurotransmitter systems maintain a certain degree of arousal.
Collectively, these observations demonstrate potent and additive wake-promoting actions of NE α 1 -and β-receptors that are necessary for the maintenance of alert waking. Much of the sedative actions of α 2 -agonists can be ascribed to autoreceptor-dependent suppression of post-synaptic α 1 -and β-receptors. The sedative actions of peri-LC α 2 -agonist infusion are consistent with this view. However, limited observations suggest that NE may inhibit sleepactive neurons via activation of α 2 -receptors in the MSA and MPOA. [46] [47] [48] 
Potential Sleep-Promoting Actions of α 1 -Receptors within the MPOA
In contrast to the robust wake-promoting effects of NE agonists infused into the MPOA and MSA, 6-OHDA lesions of the ventral noradrenergic bundle (VNAB) have been reported to increase time spent awake. 85 This has been interpreted as suggesting a potential sleeppromoting action of NE, particularly within the MPOA. 86 However, as noted above, 6-OHDA lesion of the VNAB will not eliminate all VNAB noradrenergic input to the MPOA. Moreover there are multiple sources of the noradrenergic innervation of the MPOA (LC, A1, A2), the axons of which travel through both the dorsal and VNAB (see 30 ). Combined, VNAB lesions will spare a prominent proportion of NE afferents into the MPOA while eliciting compensatory responses at the level of release and postsynaptic receptor function. [87] [88] [89] Given this, we posit that the wake-promoting effects of an incomplete VNAB lesion reflects lesion-induced upregulation of noradrenergic neurotransmission within the MPOA and/or other arousal-related structures, as has been described elsewhere (for review, see 12 ).
Lesions of the VNAB also disrupted the wake-promoting actions of NE when infused into the MPOA during the day and resulted in an NE-induced decrease in time spent awake when infused into the MPOA during the night. 90 Consistent with this latter observation, infusion of an α 1 -antagonist into the MPOA increased time spent awake. 43 Combined, these observations further suggest possible arousal-attenuating actions of MPOA α 1 -receptors. Currently, it is not clear how to reconcile the robust wake-promoting effects of intra-MPOA NE, α 1 -and β-agonist infusions reported by others [33] [34] [35] with these more recent observations. However, there are a number of issues to consider. First, these effects appear relatively modest compared to the wake-promoting effects of NE agonist infusions. Second, baseline arousal level in these latter studies appears higher and more labile than in previous studies utilizing NE agonists. Alterations in baseline arousal level could influence the arousalmodulating actions of NE. Third, when performing intra-tissue infusions, it is critical to minimize tissue damage. However, the limited available evidence indicates substantial tissue damage may have occurred within the MPOA in these more recent studies (see 91 ), which could alter the sensitivity of this region to NE-selective drugs. Fourth, given variability in baseline waking between groups observed in these studies, it would be useful to examine the effects of α 1 -antagonist infusions using a within-subject design, similar to studies with α 1 -agonists.
Behavioral State Modulatory actions of Norepinephrine Occur in Conjunction with other Behavioral Actions
Evidence reviewed above indicates potent arousal-promoting actions of the LC-NE and presumably other noradrenergic systems. However, this is not to say that the sole function of the central noradrenergic systems is the regulation of arousal. Indeed, NE-induced arousal occurs in tandem with a large variety of modulatory actions of NE on physiological and behavioral processes, including endocrine regulation, perception, motor function, attention and memory, and decision and action (for review 12 ). These actions involve a variety of cortical and subcortical noradrenergic terminal fields. A unifying theme to this diverse array of actions is the ability of NE to facilitate the collection, processing and responding to salient information arising from an ever-changing environment (for review 12 ). One component of this broad array of actions is the induction of an appropriate behavioral state for the detection of sensory events (i.e. waking). However, within the awake state, noradrenergic systems modulate a variety of systems/processes that facilitate rapid behavioral responding to environmental events and these actions can be both short-term and long-term (i.e. plasticity) in nature. Although many of these latter actions are statedependent, they are independent of an arousal regulatory function.
Clinical Relevance
The wake and arousal-promoting actions of central noradrenergic neurotransmission may have clinical relevance in a number of clinical conditions associated with the dysregulation of sleep and waking and/or arousal. For example, the data reviewed above demonstrate that under normal conditions, acute activation of LC-noradrenergic signaling is incompatible with the state of sleep. Thus, inappropriate excitatory drive on this system, which can arise from upstream regions including the prefrontal cortex and amygdala, could contribute to an inability to fall or stay asleep associated with insomnia. 92 Additionally, psychostimulants are efficacious in the treatment of narcolepsy, a disorder associated with excessive sedation. As reviewed elsewhere, these drugs potently increase noradrenergic signaling and a number of observations indicate that psychostimulant-induced activation of α 1 -and β-receptors contributes to the arousal-promoting actions of these drugs. 93 This includes the fact that amphetamine-induced arousal closely parallels druginduced elevations in extracellular levels of brain NE and the fact that amphetamine acts in brain regions linked to NE-induced arousal. 40, 94 Moreover, limited observations demonstrate that blocking actions of β-receptors prevents the EEG activating effects of intravenous amphetamine in anesthetized animals 95 . Thus, the therapeutic actions of psychostimulants in the treatment of narcolepsy may well involve the arousal/wakepromoting actions of norepinephrine.
Beyond sleep disorders, certain psychiatric disorders are associated with excessive arousal, including post-traumatic stress disorder. The sedating effect of α 1 -receptor blockade is likely relevant to the therapeutic effects of α 1 -antagonists seen in the treatment of post-traumatic stress disorder. [96] [97] [98] Finally, the arousal-promoting actions of noradrenergic α 1 -and β-receptors likely contribute to the well-documented anesthetic effects of α 2 -agonists, which suppress NE release and thus stimulation of post-synaptic α 1 -and β-receptors. 99 
Conclusion
The regulation of arousal is a critical aspect of normal behavior. A substantial body of work demonstrates a prominent role of the LC and other noradrenergic systems in the regulation of waking and arousal. NE-dependent waking/arousal involves additive/synergistic actions of α 1 -and β-receptors located within multiple subcortical regions. Combined, the available evidence indicates that under normal physiological conditions even moderate activity of the LC-NE system is incompatible with the state of sleep. Given this, excessive activity of this system may contribute to certain forms of insomnia or other conditions associated with elevated arousal levels, including stress-related disorders, such as post-traumatic stress disorder. Indeed, α 1 -antagonists are useful in treating hyperarousal associated with this disorder, including sleep disturbances. The wake-promoting actions of NE represent only one aspect of NE function and occur in tandem with noradrenergic modulation of an array of state-dependent physiological, cognitive and affective processes. Combined, these diverse actions of NE facilitate collecting, processing and acting upon sensory information.
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2.
To better determine how top-down regulation of LC discharge may impact sleep-wake regulation (e.g. prefrontal cortex → locus coeruleus; amygdala → locus coeruleus). Effects of LC activation on cortical EEG (ECoG) activity state. For these studies, the LC was first located electrophysiologically using a combined recording-infusion probe in the halothane-anesthetized rat. Once located, a 100-150 nl infusion of the cholinergic agonist, bethanechol, was made adjacent to the LC to activate LC neurons while simultaneously recording LC discharge activity. The effect of infusion-induced activation of the LC on ECoG (and hippocampal EEG, not shown) was monitored. A: Schematic of the infusion/ recording probe used to activate LC. Bethanechol was infused 300-400 μm lateral or medial to the recording electrode that was used to locate the main body of the LC. B: Photomicrograph of a peri-LC infusion site. In this example, an infusion lateral of the LC is depicted. N indicates position within the track created by the infusion needle where the infusate exited the needle. E indicates position of the recording electrode within the LC. C: Simultaneous effects of bethanechol infusion on LC activity (LC Trigger, bottom trace) and ECoG activity (top trace). Bethanechol infusion (indicated by horizontal bar) increased LC discharge rate approximately two-thirds of the way through the 60-second infusion. Several seconds following LC activation, EEG desynchronization is observed. EEG recordings were ipsilateral to the manipulated LC. However, identical effects were observed in the contralateral hemisphere. D: Power spectral analyses of 11-second pre-infusion and postinfusion ECoG epochs. Power of low-frequency activity is decreased following bethanecholinduced activation of ECoG. E: Schematic depicting bethanechol infusion sites that were effective or ineffective for activating forebrain EEG. Solid circles indicate sites at which bethanechol infusion activated EEG. Shaded boxes indicate sites at which bethanechol infusion had no obvious EEG effects. There is a radius of approximately 500 μm around LC within which infusions, placed either medially or laterally, activated forebrain EEG. Infusions placed immediately anterior to the LC were also ineffective (not shown). These mapping studies strongly argue against drug action at other arousal-related brainstem nuclei (e.g. cholinergic, serotonergic). Abbreviations: Me5, mesencephalic nucleus of the trigeminal nerve; Mo5, motor nucleus of the trigeminal nerve; Pr5, principle sensory nucleus of the trigeminal nerve; 4V, fourth ventricle (from 22 ). Effects of bilateral suppression of LC discharge in the lightly-anesthetized rat. A similar experimental approach was taken to that outlined in Figure 1 , other than 1) animals were lightly anesthetized and 2) they received bilateral peri-LC clonidine infusions (35, 100 ng/ 35, 100 nl). The top panels (LC) depict oscilloscope traces of a multiunit LC recording before (Pre-Clonidine) and after (Post-Clonidine) a peri-LC clonidine infusion. Clonidine completely suppressed LC discharge. The effects of LC suppression on cortical EEG (ECoG, middle panels) and hippocampal EEG (HEEG, bottom panels) were characterized. Shown are 25-second raw ECoG/HEEG traces along with the results of power spectral analysis (graphs below raw traces). Power spectral analysis was calculated on 8-minute epochs that included the 25-second EEG segment shown. Prior to clonidine infusion, baseline EEG was stably activated as indicated by limited slow-wave activity in cortical EEG (ECoG, middle panels) and nearly pure theta activity in hippocampal EEG (HEEG, bottom panels). Peri-LC clonidine infusions that completely suppressed LC discharge bilaterally resulted in a profound increase in slow-wave activity in ECoG and HEEG recordings and a decrease in theta activity in HEEG. These effects appeared within secondsminutes of LC suppression and persisted for the entire period in which LC neurons were completely inactive (> 60-90 minutes). Recovery from these EEG effects quickly followed the emergence of minimal LC discharge activity. Shading in the power spectral plots indicates the theta frequency band (2.3-6.9 Hz) in the HEEG power spectra. Mapping studies indicated an ~500-600μm radius around the LC for clonidine-induced increases in EEG indices of sedation (from 23 ). The only exception to this was observed with the high dose of NE. In this case the latency to waking was longer, the magnitude of waking smaller and the duration shorter than that observed with infusions into the MPOA. The wake-promoting effects of intra-MPOA infusion of all of these compounds are dose-dependent. Larger effects are observed with bilateral infusions. Similar wake-promoting effects of β and α 1 -receptor activation are observed in MSA. Bottom Panel: Effects of vehicle and PHEN (10 nmol, 50 nmol) infusion into the MSA on time spent awake. PHEN exerts dose dependent wake-promoting effects when infused into the MSA. Similar effects were observed with infusion of the β-agonist, ISO. For all panels, a lack of visible error bars indicates the magnitude of the SEM fell within the range corresponding to the dimensions of the symbol. There were no significant differences between any of the groups during the pre-infusion epochs. * P<0.05, ** P<0.01 compared to PRE-1 (from 31-33, 40 }). NE acts within the LH to promote alert waking. Shown are the effects of bilateral intra-LH infusion of the α 1 -agonist, phenylephrine (PHEN; 20 nmol/250 nl) on time spent awake as determined from EEG/EMG indices. At this dose, PHEN increased time spent awake for a sustained period. Unilateral infusions also produced significant increases in waking, but of a somewhat lesser intensity. Intra-LH β-agonist infusion produced smaller magnitude, though significant, wake-promoting effects (data not shown). Synergistic sedative effects of α 1 -and β-receptor blockade globally within the brain. Shown are the effects of the β-antagonist, timolol (ICV), the α 1 -antagonist, prazosin (IP) and combined antagonist treatment on cortical EEG in animals exposed to an arousing brightlylit novel environment. Animals were treated 30-minutes prior to testing with: 1) ICV vehicle + IP saline (VEH/VEH); 2) 150 μg ICV timolol + IP saline (TIM/VEH); 3) ICV vehicle + IP 500 μg/kg prazosin (VEH/PRAZ,), and; 4) combined timolol + prazosin (TIM/PRAZ). In this figure, EEG traces are from the second 5-min epoch of exposure to the novel environment. Vehicle-treated controls displayed behavioral and EEG indices of alert waking throughout most of the recording session. This was reflected in sustained EEG desynchronization (low-amplitude, high-frequency). β-receptor blockade alone (TIM/VEH) had no effects on EEG activity. α 1 -receptor blockade alone (VEH/PRAZ) increased the frequency and duration of sleep spindles (high-voltage spindles). In contrast to that observed with β-receptor blockade alone, in the presence of α 1 -receptor blockade, β-receptor blockade produced substantial increases in large-amplitude, slow-wave activity. Power spectral analysis quantified and confirmed these qualitative observations (data not shown; from 62 ).
